CVRx Inc. in Plymouth, Minn. said Monday that hypertension patients using its Rheos stimulation device reported a sharp drop in blood pressure after four years.In a study presented to the European Society of Hypertension meeting, the company said patients’ average systolic blood pressure dropped 27 percent to 140 mmHg (millimeters of mercury) from 193 mmHg [...]
[Read more of this report]Updated 6:47 p.m.Small molecule discovery and development company Akebia Therapeutics Inc. reported positive results from a second Phase 1 clinical trial of its anemia drug, as well as the second closing of a $16 million financing round announced almost a year ago, boosting the round to $17 million.var page_count = “off”; [...]
[Read more of this report]The company stated it raised additional money to ensure the development of two of its drugs. Akebia plans later this year to start Phase I clinical trials on an oral medication designed to create new red blood cells in anemia patients. In addition, it wants to establish a human clinical proof of concept for a second drug that prevents vascular leak syndrome, in which blood components leak out of veins and into other systems — a side effect of some cancer treatments.
[Read more of this report]